Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: An in vivo study in orthotopic xenografts of nude mice

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1729-1739

  Xu, Xiaofei ^a,c   Ayub, Bushra ^c   Liu, Zhaojian ^b,c   Serna, Vanida Ann ^c,f   Qiang, Wenan ^c   Liu, Yugang ^c   Hernando, Eva ^d   Zabludoff, Sonya ^e   Kurita, Takeshi ^c,f   Kong, Beihua ^a   Wei, Jian Jun ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e REGULUS THERAPEUTICS   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; CHECKPOINT KINASE 2; CLYD PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA 182; MTSS1 PROTEIN; PDCD4 PROTEIN; PROTEIN; PROTEIN RECK; RNA ANTIBODY; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; MICRORNA; MIRN182 MICRORNA, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO IMAGING ANALYSIS; KIDNEY METASTASIS; LIVER METASTASIS; MOUSE; NONHUMAN; OMENTUM METASTASIS; OVARIAN CANCER CELL LINE; OVARIECTOMY; OVARY CARCINOMA; PANCREAS METASTASIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN METASTASIS; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; LUMINESCENCE; METASTASIS; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RANDOM ALLOCATION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904151743     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0982     Document Type: Article

References (31)

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64.
2. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 2012;228:204-15.
3. McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, et al. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod Pathol 2012;25:1644-53.
4. Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010;116:117-25.
5. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907. (Pubitemid 351482843)
6. McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, et al. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod Pathol 2012;25:1644-53.
7. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009;106:1814-9.
8. Lei R, Tang J, Zhuang X, Deng R, Li G, Yu J, et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene 2014;33:1287-96.
9. Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One 2013;8:e55502.
10. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011;30:1481-8.
11. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 2011;71:349-59.
12. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. MiR182 overexpression in tumorigenesis of high-grade ovarian papillary serous carcinoma. J Pathol 2012;228:204-15.
13. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
14. Galimi F, Torti D, Sassi F, Isella C, Cora D, Gastaldi S, et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res 2011;17:3146-56.
15. Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One 2011;6:e25264.
16. Krishnan K, Steptoe AL, Martin HC, Wani S, Nones K, Waddell N, et al. MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA 2013;19:230-42.
17. Chiang CH, Hou MF, Hung WC. Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 2013;1830:3067-76.
18. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011;6:e18064.
19. Fong MY, Kakar SS. Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res 2009;2:12.
20. Heskamp S, Laverman P, Rosik D, Boschetti F, van der Graaf WT, Oyen WJ, et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med 2012;53:146-53.
21. Zacchetti A, Martin F, Luison E, Coliva A, Bombardieri E, Allegretti M, et al. Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J Nucl Med 2011;52:1938-46.
22. Cordero AB, Kwon Y, Hua X, Godwin AK. In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp 2010 Aug 17.
23. Liu H, Du L, Wen Z, Yang Y, Li J, Wang L, et al. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis 2013;28:697-703.
24. Gu C, Li X, Tan Q, Wang Z, Chen L, Liu Y. MiR-183 family regulates chloride intracellular channel 5 expression in inner ear hair cells. Toxicol In Vitro 2013;27:486-91.
25. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, et al. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One 2012;7:e51056.
26. Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, et al. TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest 2012;122:3563-78.
27. Saarikangas J, Mattila PK, Varjosalo M, Bovellan M, Hakanen J, Calzada-Wack J, et al. Missing-in-metastasis MIM/MTSS1 promotes actin assembly at intercellular junctions and is required for integrity of kidney epithelia. J Cell Sci 2011;124:1245-55.
28. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
29. Fedele M, Pierantoni GM, Visone R, Fusco A. Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006;5:2045-8. (Pubitemid 44553735)
30. Wu J, Wei JJ. HMGA2 and high-grade serous ovarian carcinoma. J Mol Med (Berl) 2013;91:1155-65.
31. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010;28:341-7.